In recent years, tumor immunotherapy has made significant progress. However, tumor
immunotherapy, particularly immune checkpoint inhibitors (eg, PD-1/PD-L1 inhibitors) …

Abstract Immune-checkpoint inhibitors (ICI), particularly inhibitors of the PD-1 axis, have
altered the management of non–small cell lung cancer (NSCLC) over the last 10 years. First …

Despite neoadjuvant/conversion chemotherapy, the prognosis of cT4a/bN+ gastric cancer is
poor. Immune checkpoint inhibitors (ICIs) and antiangiogenic agents have shown activity in …

Abstract Background The PD-1/PD-L1 checkpoint is a central mediator of
immunosuppression in the tumor immune microenvironment (TME) and is primarily …

The highly complex and heterogenous ecosystem of a tumour not only contains malignant
cells, but also interacting cells from the host such as endothelial cells, stromal fibroblasts …

The clinical development of checkpoint inhibitor-based immunotherapy has ushered in an
exciting era of anticancer therapy. Durable responses can be seen in patients with …

Despite the impressive impact of CTLA 4 and PD 1‐PDL 1‐targeted cancer immunotherapy,
a large proportion of patients with many tumor types fail to respond. Consequently, the focus …

With recent approvals for multiple therapeutic antibodies that block cytotoxic T lymphocyte
associated antigen 4 (CTLA4) and programmed cell death protein 1 (PD1) in melanoma …

Immune checkpoint blockade produces clinical benefit in many patients. However, better
biomarkers of response are still needed, and mechanisms of resistance remain incompletely …

Checkpoint blockade (CPB) therapy can elicit durable clinical responses by reactivating an
exhausted immune response. However, response rates remain limited, likely secondary to a …